Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.
Demographics of patients with recurrent GBM by treatment group evaluated with DG scores
| BevAlone | BevCyto | |
|---|---|---|
| N | 24 | 38 |
| Sex | ||
| Male | 14 (58%) | 28 (74%) |
| Female | 10 (42%) | 10 (26%) |
| Age (start of treatment) | ||
| Mean (range) | 54.8 (20–77) | 58.0 (22–79) |
| DG T1GD | ||
| Median | 134.4 | 95.9 |
| Range | (−852.7, 648.7) | (−66.76, 702) |
| DG FLAIR | ||
| Median | 121.3 | 57.8 |
| Range | (−643.3, 630.7) | (−921.4, 390.7) |
Patients received either bevacizumab monotherapy (BevAlone) or bevacizumab concurrent with a cytotoxic therapy (BevCyto).
